(Q39612011)

English

Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines

scientific article published on 8 April 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 September 2017

Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines (English)

1 reference

Europe PubMed Central

13 September 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

phosphorylation

1 reference

based on heuristic

inferred from title

esophageal cancer

1 reference

based on heuristic

inferred from title

author name string

Kousaku Mimura

1

1 reference

Europe PubMed Central

13 September 2017

Koji Kono

2

1 reference

Europe PubMed Central

13 September 2017

Takanori Maruyama

3

1 reference

Europe PubMed Central

13 September 2017

Mitsuaki Watanabe

4

1 reference

Europe PubMed Central

13 September 2017

Shinichiro Izawa

5

1 reference

Europe PubMed Central

13 September 2017

Shugo Shiba

6

1 reference

Europe PubMed Central

13 September 2017

Yoshiki Mizukami

7

1 reference

Europe PubMed Central

13 September 2017

Yoshihiko Kawaguchi

8

1 reference

Europe PubMed Central

13 September 2017

Masayuki Inoue

9

1 reference

Europe PubMed Central

13 September 2017

Tetsuo Kono

10

1 reference

Europe PubMed Central

13 September 2017

Aniruddha Choudhury

11

1 reference

Europe PubMed Central

13 September 2017

Rolf Kiessling

12

1 reference

Europe PubMed Central

13 September 2017

Hideki Fujii

13

1 reference

Europe PubMed Central

13 September 2017

language of work or name

0 references

publication date

8 April 2011

1 reference

Europe PubMed Central

13 September 2017

International Journal of Cancer

1 reference

Europe PubMed Central

13 September 2017

129

1 reference

Europe PubMed Central

13 September 2017

2408-2416

1 reference

Europe PubMed Central

13 September 2017

10

1 reference

Europe PubMed Central

13 September 2017

Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407).

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

Untangling the ErbB signalling network

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

EGF-ERBB signalling: towards the systems level

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

Transduction with the antioxidant enzyme catalase protects human T cells against oxidative stress

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

Visualization by fluorescence of the binding and internalization of epidermal growth factor in human carcinoma cells A-431

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

Radical Lymph Node Dissection for Cancer of the Thoracic Esophagus

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25896

21 January 2018

Identifiers

10.1002/IJC.25896

1 reference

Europe PubMed Central

13 September 2017

1 reference

Europe PubMed Central

13 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39612011&oldid=1845413708"